Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes – The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the...
HIPAA Encryption for iPhones and Android Phones June 17, 2014 Sending Encrypted ePHI to Mobile Devices When new regulations were enacted in the Health Insurance Portability and Accountability Act (HIPAA) in March 2013, healthcare organizations had to decide how to...
Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results – Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies – Company to Hold Conference Call at 5:00 p.m. EDT (4:00 p.m. CDT) CHICAGO, June 23, 2014...
Pharmacy Pricing & Benefits Analysis Platform Truveris Raised Another $12.75M Series C Round Financing led by Canaan Partners NEW YORK, June 27, 2014 — Truveris, a leading platform for pharmacy pricing and benefits analysis, today announced it raised $12.75...
ReShape Medical® Submits PMA Application to FDA for Non-Surgical Weight Loss Device ReShape™ Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum SAN CLEMENTE, Calif., July 1, 2014 – ReShape Medical® today announced that the Company has...
Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499 Provides Direction for Phase 3 Development in Diabetic Nephropathy LEXINGTON, Mass.–(July 8, 2014)– Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the...
Recent Comments